Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diltiazem. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1S known ✓ | Q13698 | 11/20 | 1.00 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 1.00 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 1.00 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | SCN1A | P35498 | 1/20 | 1.00 |
| ▸ | SCN4A | P35499 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | SCN7A | Q01118 | 1/20 | 1.00 |
| ▸ | PLAUR | Q03405 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | SCN9A | Q15858 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diltiazem SCHEMBL3468378 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL29353951 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL30127237 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL676914 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL614334 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL4886734 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL13575826 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL30127157 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL10831293 | 0.99 | CYP3A4 (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL8545465 | 0.99 | CYP3A4 (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 59418 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| WO-2026103722-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COAGULATION FACTOR XI (FXI) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2026-05-21 | — | — | WO | claimed |
| WO-2026107071-A1 | COMBINATION THERAPY | Retension Pharmaceuticals, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| WO-2026102345-A1 | METHODS OF ADMINISTERING THE VOLTAGE-GATED POTASSIUM CHANNEL OPENER AZETUKALNER | XENON PHARMACEUTICALS INC. (CA) | 2026-05-15 | — | — | WO | claimed |
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-0149920-A2 | Pharmaceutical formulation | ELAN CORPORATION, Plc (IE) | 1985-07-31 | — | — | EP | claimed |
| US-4520112-A | RADIOACTIVE LABELING | THE JOHNS HOPKINS UNIVERSITY (US) | 1985-05-28 | — | — | US | claimed |
| US-4504476-A | Method of administering calcium channel blocking agents | SCHWARTZ ARNOLD | 1985-03-12 | — | — | US | claimed |
| EP-0133252-A1 | Galenic form for the administration by inhalation of calcium antagonists | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1985-02-20 | — | — | EP | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
| EP-0123850-A2 | Inhibition of tumor growth and metastasis with calcium channel blocker compounds | THE BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) | 1984-11-07 | — | — | EP | claimed |
| EP-0107095-A1 | 1-N-alkylcarboxy-benzofused lactams useful as antihypertensive agents | MERCK & CO. INC. (US) | 1984-05-02 | — | — | EP | claimed |
| EP-0106335-A2 | Pharmaceutical composition and a method for enhancing the absorption of a pharmaceutically active compound | Tanabe Seiyaku Co., Ltd. (JP) | 1984-04-25 | — | — | EP | claimed |
| US-4369172-A | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose | FOREST LABORATORIES INC. (US) | 1983-01-18 | — | — | US | claimed |
| US-4218466-A | Method of treating gastric and duodenal ulcers | SYNTHELABO (FR) | 1980-08-19 | — | — | US | claimed |